Through the work of Huggins et al.  in 1941, it was shown that metastatic prostate cancer responds positively to an orchiectomy (surgical castration). We now know that there isn’t any other therapy which produces a more reliable regression of both distant and local disease than androgen withdrawal (ADT).
There is often a choice is between using the LHRH agonist drug (Lupron, Trelstar) or using the gonadotrophin-releasing hormone (GnRH) antagonist like Firmagon.
This brings us to the question, which of these two drugs is superior?
A study found that African American men had a higher rate of death from non-prostate cancer problems than non-African American men after receiving short-term hormone therapy (ADT) prior to having brachytherapy (seeds). There are significant implications beyond this research for African Americans using ADT for any purpose, including he treatment of advanced (progressive) prostate cancer.